FDA approves Pharming's Joenja as first treatment for children with APDS in the U.S.
Globe Newswire (Fri, 11-Sep 1:59 PM ET)
Pharming wins approval of Joenja for younger age group
Seeking Alpha News (Fri, 11-Sep 1:10 PM ET)
Pharming Group to participate in September investor conferences
Globe Newswire (Wed, 9-Sep 2:00 AM ET)
Globe Newswire (Thu, 13-Aug 1:00 AM ET)
Pharming Group (PHAR) Securities Investigation Notice - Levi & Korsinsky
PRNewswire (Fri, 7-Aug 10:05 AM ET)
Business Wire (Thu, 6-Aug 11:00 AM ET)
Business Wire (Thu, 6-Aug 9:00 AM ET)
Business Wire (Wed, 5-Aug 3:17 PM ET)
Globe Newswire (Wed, 5-Aug 10:05 AM ET)
PHAR Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Pharming Group (PHAR)
Business Wire (Tue, 4-Aug 10:07 AM ET)
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
Pharming Group N.V. - Ads Each Representing 10 trades on the NASDAQ stock market under the symbol PHAR.
As of September 11, 2026, PHAR stock price climbed to $11.28 with 34,379 million shares trading.
PHAR has a beta of 0.49, meaning it tends to be less sensitive to market movements. PHAR has a correlation of 0.01 to the broad based SPY ETF.
PHAR has a market cap of $798.38 million. This is considered a Small Cap stock.
Last quarter Pharming Group N.V. - Ads Each Representing 10 reported $90 million in Revenue and $.02 earnings per share. This fell short of revenue expectation by $-11 million and missed earnings estimates by -$.07.
In the last 3 years, PHAR traded as high as $21.34 and as low as $6.65.
PHAR has underperformed the market in the last year with a price return of -16.5% while the SPY ETF gained +18.5%. PHAR has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -8.1% and -4.2%, respectively, while the SPY returned +5.7% and -0.8%, respectively.
PHAR support price is $10.44 and resistance is $11.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PHAR shares will trade within this expected range on the day.
